MedTrace Logo

A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)

NCT00665522 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2015-04-10

No results posted yet for this study

Summary

The purpose of the study is to document the use of fentanyl HCl 40 mcg system under routine conditions and obtain a more comprehensive understanding of the safety of the system and complications that may not be spontaneously reported.

Conditions

Interventions

DRUG

fentanyl iontophoretic transdermal system (40mcg) No Placebo

40 mcg per dose, maximum of 6 doses/hour

DRUG

IV PCA with standard of care opioid analgesia

total maximum 80 doses/24 hours

Sponsors & Collaborators

  • Alza Corporation, DE, USA

    lead INDUSTRY

Principal Investigators

  • Alza Corporation Clinical Trial · ALZA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Austria
  • Finland
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665522 on ClinicalTrials.gov